News

2018

The National Cancer Institute has awarded Proteovista's SBIR Grant, Site-Specific Incorporation of Phosphorylation Modifications on the SNAP-Tide High Density Peptide Array

Proteovista has been awarded a SBIR Advance Phase I Match Grant from the Wisconsin Center for Technology Commercialization, August 2017

Proteovista presented "High Throughput Analysis of the DNA Binding Specificity of Estrogen Receptor and Estrogen Related Receptor Complexes," Keystone Symposium Nuclear Receptors: Full Throttle in Snowbird, UT.

Proteovista presented invited talk to U.S. Representative Mark Pocan at University Research Park.
Proteovista presented “High Density Peptide Arrays for Cancer-Related Post-Translational Modifications" at the IMAT Symposium in Bethesda, MD.
Proteovista presented "Discovery of Small Molecule Modulators Targeting Estrogen Receptor-FoxA1-DNA Interactions Using SNAP-Screen DNA Arrays" at FASEB meeting in Big Sky, MT.
Proteovista awarded Wisconsin Small Business Innovation Award for Outstanding Achievements.

The National Institutes of Health has awarded Proteovista a three-year, $643,000 grant to develop a new microarray platform for identifying biomarkers associated with various cardiovascular diseases.
"SNP-SNAP Binding Arrays Reveal SNPs that Modulate Transcription Factor Interactions in Prostate Cancer" selected for a talk at the ENDO Society meeting in Chicago.
Proteovista Co-Founder prevails in lawsuit against VistaMotif LLC and Professor Aseem Ansari.
Proteovista presented "High Throughput Strategies to Identify Small Molecule Modulators of Estrogen Receptor - DNA Interactions" at the Keystone Symposia in Taos, New Mexico.
Proteovista is awarded a three year R21 grant by the NIH for the development of a high density peptide array to study human post-translational modifications.

2013

2012

The United States Department of Defense grants a Pilot Award in ovarian cancer research to Proteovista LLC.
Proteovista launches its SNAP technology as a custom service.
Proteovista awarded Wisconsin Small Business Innovation Award for Outstanding Achievements.

2011

Proteovista is awarded an NIH Phase I SBIR to develop novel breast cancer therapeutics
Protevista is awarded a highly competitive National Cancer Institute IMAT (Innovative Molecular Analysis Technologies) grant to study genetic variations in prostate cancer incidence.
Drs. Warren and Ozers give an invited research presentation at the Era of Hope Breast Cancer Research Conference sponsored by the Department of Defense and Congressionally Directed Medical Research Programs.

Principal Investigators, Drs. Warren and Ozers, completed Small Business Innovation Research (SBIR) Phase I in April 2010 and Department of Defense Concept Award in September 2010.
Collaborated on the Research Poster, "Effect of Bisphenol A on the Comprehensive DNA Recognition Profile of Estrogen-Related Receptor Gamma and Estrogen Receptor Alpha in Breast Cancer Cells," at the 92nd Annual Meeting of the Endocrine Society, San Diego CA, June 2010.